Amendment to the Claims

1. (Currently amended): A compound of the formula (I),



(I)

A1

the racemic-diastereomeric mixtures and optical isomers of said compound of formula (I) ~~, the pharmaceutically acceptable salts and prodrugs thereof~~ or a pharmaceutically acceptable salt thereof,

wherein

------- represents an optional bond;

R^1 is H, $-(CH_2)_m-C(O)-(CH_2)_m-Z^1$, $-(CH_2)_m-Z^1$, $-(CH_2)_m-O-Z^1$ or $-(C_0-C_6)$alkyl-C(O)-NH-$(CH_2)_m-Z^3$;

Z^1 is an ~~optionally substituted~~ unsubstituted or substituted moiety selected from the group consisting of (C_1-C_{12})alkyl, benzo[b]thiophene, phenyl, naphthyl, benzo[b]furanyl, thiophene, isoxazolyl, indolyl,  ;

R^2 is H or (C_1-C_6)alkyl;

or R^1 and R^2 are taken together with the nitrogen atoms to which they are attached to form a compound of formula (Ia), (Ib) or (Ic),



(Ia) , (Ib) or (Ic) ;

R^3 is $-(CH_2)_m-E-(CH_2)_m-Z^2$;

E is O, S,-C(O)-, -C(O)-O-, -NH-C(O)-O- or a bond;

Z^2 is H, (C_1-C_{12})alkyl, amino, (C_1-C_{12})alkylamino, N,N-di-(C_1-C_{12})alkylamino, (C_1-C_{12})alkylguanidino, or an ~~optionally substituted~~ unsubstituted or substituted moiety selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl and naphthyl;

R^4 is H or $-(CH_2)_m-A^1$;

A^1 is $-C(=Y)-N(X^1X^2)$, ~~$-C(=Y)-X^2$, $-C(=NH)-X^2$ or X^2~~;

Y is O or S;

X^1 is H, (C_1-C_{12})alkyl, $-(CH_2)_m-NH-(C_1-C_6)$alkyl, $-(CH_2)_m-N$-di-(C_1-C_6)alkyl or $-(CH_2)_m$-aryl;

X^2 is $-(CH_2)_m-Y^1-X^3$ or ~~optionally substituted~~ unsubstituted or substituted (C_1-C_{12})alkyl;

Y^1 is O, S, NH, C=O, (C_2-C_{12})alkenyl having one or more double bonds, -NH-CO-, -CO-NH-, $-NH-CO-O-(CH_2)_m-$, $-C\equiv C-$, SO_2 or a bond;

X^3 is H, an ~~optionally substituted~~ unsubstituted or substituted moiety selected from the group consisting of (C_1-C_{12})alkyl, (C_3-C_8)cycloalkyl, (C_1-C_{12})alkoxy, aryloxy, (C_1-C_{12})alkylamino, N,N-di-(C_1-C_{12})alkylamino, -CH-di-(C_1-C_{12})alkoxy, pyrrolidinyl, pyridinyl, thiophene, imidazolyl, piperidinyl, piperazinyl, benzothiazolyl, furanyl, indolyl, morpholino, benzo[b]furanyl, quinolinyl, isoquinolinyl, $-(CH_2)_m$-phenyl, naphthyl, fluorenyl, phthalamidyl, pyrimidinyl,







A1

or X^1 and X^2 are taken together with the nitrogen to which they are attached to form an ~~optionally substituted~~ unsubstituted or substituted moiety selected from the group consisting of thiazolyl





Y^2 is CH-X^4, N-X^4, -C(X^4X^4), O or S;

X^4 for each occurrence is independently -$(CH_2)_m$-Y^3-X^5;

Y^3 is -C(O)-, -C(O)O- or a bond;

X^5 is hydroxy, (C_1-C_{12})alkyl, amino, (C_1-C_{12})alkylamino, N,N-di-(C_1-C_{12})alkylamino, or an ~~optionally substituted~~ unsubstituted or substituted moiety

selected from the group consisting of aryl, aryl(C_1-C_4)alkyl, furanyl, pyridinyl, indolyl, -CH(phenyl)$_2$,



;

R^5 is (C_1-C_{12})alkyl, (C_0-C_6)alkyl-C(O)-O-Z^5, (C_0-C_6)alkyl-C(O)-NH-$(CH_2)_m$-Z^3 or ~~optionally substituted~~ unsubstituted or substituted aryl;

Z^3 for each occurrence is independently amino, (C_1-C_{12})alkylamino, N,N-di-(C_1-C_{12})alkylamino, -NH-C(O)-O-$(CH_2)_m$-phenyl -NH-C(O)-O-$(CH_2)_m$-(C_1-C_6)alkyl or an ~~optionally substituted~~ unsubstituted or substituted moiety selected from the group consisting of imidazolyl, pyridinyl, morpholino, piperidinyl, piperazinyl, pyrazolidinyl, furanyl and thiophene;

R^6 is H or (C_1-C_6)alkyl;

R^7 is (C_1-C_{12})alkyl or -$(CH_2)_m$-Z^4;

Z^4 is an ~~optionally substituted~~ unsubstituted or substituted moiety selected from the group consisting of phenyl, naphthyl, indolyl, thiophene, benzo[b]furan, benzo[b]thiophene, isoxazolyl,



;

Z^5 is H, (C_1-C_{12})alkyl, $(CH_2)_m$-aryl;

wherein an ~~optionally substituted~~ unsubstituted or substituted moiety is ~~optionally~~ substituted by one or more substituents, each independently selected from the group consisting of Cl, F, Br, I, CF_3, CN, N_3, NO_2, OH, SO_2NH_2, -OCF_3, (C_1-C_{12})alkoxy, -$(CH_2)_m$-phenyl-$(X^6)_n$, -S-phenyl-$(X^6)_n$, -S-(C_1-C_{12})alkyl, -O-$(CH_2)_m$-phenyl-$(X^6)_n$, -$(CH_2)_m$-C(O)-O-(C_1-C_6)alkyl, -$(CH_2)_m$-C(O)-(C_1-C_6)alkyl, -O-$(CH_2)_m$-NH_2, -O-$(CH_2)_m$-NH-(C_1-C_6)alkyl, -O-$(CH_2)_m$-N-di-((C_1-C_6)alkyl) and -(C_0-C_{12})alkyl-$(X^6)_n$;

X^6 for each occurrence is independently selected from the group consisting of hydrogen, Cl, F, Br, I, NO_2, N_3, CN, OH, -CF_3, -OCF_3, (C_1-C_{12})alkyl, (C_1-C_{12})alkoxy, -$(CH_2)_m$-NH_2, -$(CH_2)_m$-NH-(C_1-C_6)alkyl, -$(CH_2)_m$-N-di-((C_1-C_6)alkyl) and -$(CH_2)_m$-phenyl;

m for each occurrence is independently 0 or an integer from 1 to 6; and

n for each occurrence is independently an integer from 1 to 5;

provided that:

(a) when R^5 is $(C_1\text{-}C_{12})$alkyl or $(C_0\text{-}C_6)$alkyl-C(O)-O-Z^5 and Z^5 is $(C_1\text{-}C_{12})$alkyl or an ~~optionally substituted~~ unsubstituted or substituted aryl; R^6 is H or $(C_1\text{-}C_6)$alkyl; R^7 is $(C_1\text{-}C_{12})$alkyl or Z^4 and Z^4 is thiophene or an ~~optionally substituted~~ unsubstituted or substituted phenyl, then R^3 is not -C(O)-O-$(CH_2)_m$-Z where m is 0 and Z is H or $(C_1\text{-}C_{12})$alkyl or where m is 1 to 6 and Z is H;

(b) when R^5 is $(C_1\text{-}C_{12})$alkyl or an ~~optionally substituted~~ unsubstituted or substituted phenyl; R^6 is H or $(C_1\text{-}C_{12})$alkyl; R^7 is $(C_1\text{-}C_{12})$alkyl and R^3 is -O-(CH_2)-Z^2, then Z^2 is not an ~~optionally substituted~~ unsubstituted or substituted moiety selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl, and naphthyl; ~~and~~

(c) when R^5 is H or $(C_1\text{-}C_{12})$alkyl; R^6 is $(C_1\text{-}C_6)$alkyl; R^7 is $(C_1\text{-}C_{12})$alkyl; and R^3 is -O-Z^2 or -S-Z^2, then Z^2 is not an ~~optionally substituted~~ unsubstituted or substituted moiety selected from the group consisting of phenyl, naphthyl, thiophene, benzothienyl and indolyl~~.~~; and

(d) when R^1 is H; R^2 is H; R^5 is a substituted aryl; and R^6 is H, R^3 is not -$(CH_2)_m$-E-$(CH_2)_m$-Z^2 wherein each occurrence of m is 0, E is a bond and Z^2 is H.

2. (Original): A compound according to claim 1 wherein R^1 is H; R^2 is H; R^3 is -CH_2-phenyl; R^4 is -$(CH_2)_m$-A^1 where m in the definition of R^4 is 0; R^5 is phenyl; R^6 is H;

where A^1 is -C(=Y)-N(X^1X^2);

Y is O; X^1 is H or methyl;

X^2 is -$(CH_2)_m$-Y^1-X^3;

m in the definition of X^2 is 0, 1, 2 or 3; Y^1 is a bond or O; and X^3 is N-methylpyrrolidin-2-yl, diethylamino, pyridinyl, thiophene, imidazolyl, diethoxymethyl, 1-benzyl-piperidin-4-yl, unsubstituted or substituted phenyl or



3. (Original): A compound according to claim 1 wherein R^1 is H; R^2 is H; R^3 is -CH_2-phenyl; R^4 is -$(CH_2)_m$-A^1 where m in the definition of R^4 is 0; R^5 is phenyl; R^6 is H;

where A^1 is -C(=Y)-N(X^1X^2);

Y is O;

X^1 is benzyl and X^2 is 2-hydroxyethyl;

or X^1 and X^2 are taken together with the nitrogen atom to which they are attached to form  ;

where Y^2 is C-X^4 or N-X^4;

X^4 is -$(CH_2)_m$-Y^3-X^5 where m in the definition of X^4 is 0 or 1; and

X^5 is selected from the group consisting of furanyl, benzyl, phenyl, amino, 

A1

4. (Withdrawn):

5. (Original): A compound according to claim 1 wherein R^1 is H; R^2 is H; R^3 is -CH_2-indol-3-yl; R^4 is -$(CH_2)_m$-A^1 where m in the definition of R^4 is 0; R^5 is phenyl or t-Bu; R^6 is H;

A^1 is -C(=Y)-N(X^1X^2);

Y is O or S; X^1 is H; X^2 is -$(CH_2)_m$-Y^1-X^3;

m in the definition of X^2 is 0, 1 or 2;

Y^1 is a bond; and X^3 is phenyl, o-Cl-phenyl, m-Cl-phenyl, p-phenyloxy-phenyl, 2,6-di-isopropylphenyl, m-CF_3-phenyl, p-ethoxycarbonyl-phenyl, 2,4-difluorophenyl, m-NO_2-phenyl, p-benzyloxyphenyl, o-isopropylphenyl, n-hexyl, 4-morpholino, naphthyl or 

6. (Withdrawn):

7. (Original): A compound according to claim 1 wherein R^1 is H; R^2 is H; R^3 is -CH_2-indol-3-yl; R^4 is -$(CH_2)_m$-A^1 where m in the definition of R^4 is 0; R^5 is phenyl or t-Bu; R^6 is H;

where A^1 is -C(=Y)-N(X^1X^2);

Y is O; X^1 is hydrogen; X^2 is -$(CH_2)_m$-Y^1-X^3;

where m in the definition of X^2 is 0, 1, 2 or 3;

Y^1 is O, or a bond; and X^3 is cyclopentyl, 4-OH-butyl, N,N-diethylamino, N-methyl-pyrrolidin-3-yl, -CH(ethoxy)$_2$, phenyl, p-SO_2NH_2-phenyl p-OH-phenyl, o-CF_3-phenyl, p-Cl-phenyl, -CH(phenyl)$_2$,



8. (Withdrawn):

A1 9. (Original): A compound according to claim 1 wherein R^1 is H; R^2 is H; R^3 is -CH_2-indol-3-yl, -$(CH_2)_4$-NH-CO-O-t-Bu or -$(CH_2)_4$-NH_2; R^4 is -$(CH_2)_m$-A^1 where m in the definition of R^4 is 0; R^5 is phenyl, o-methoxyphenyl, p-Br-phenyl, p-nitro-phenyl or p-N,N-diethylamino-phenyl; R^6 is H;

where A^1 is -C(=Y)-N(X^1X^2);

Y is O; X^1 is H; X^2 is -$(CH_2)_m$-Y^1-X^3;

where m in the definition of X^2 is 0;

Y^1 is a bond; and X^3 is o-Br-phenyl, m-Br-phenyl, p-Br-phenyl, o-Cl-phenyl, m-Cl-phenyl, p-Cl-phenyl, o-nitro-phenyl, m-nitro-phenyl, p-nitro-phenyl, o-CF_3-phenyl, m-CF_3-phenyl, p-CF_3-phenyl, p-F-phenyl, 2,4-di-F-phenyl, 2,5-di-F-phenyl, 2,5-di-methoxy-phenyl, m-OMe-phenyl, p-OMe-phenyl, 2-CF_3-4-Cl-phenyl or 3-nitro-4-F-phenyl.

10. (Withdrawn):

11. (Original): A compound according to claim 9 wherein R^5 is phenyl and R^3 is -(CH_2)-indol-3-yl and the stereochemistry at the carbon to which R^3 is attached is the R-configuration.

12. (Withdrawn):

13. (Withdrawn):

14. (Withdrawn):

15. (Withdrawn):

16. (Withdrawn):

17. (Withdrawn):

18. (Withdrawn):

19. (Withdrawn):

20. (Withdrawn):

21. (Withdrawn):

22. (Currently Amended): A compound of the formula (II),



(II)

the racemic-diastereomeric mixtures and optical isomers of said compound of formula (II), ~~the pharmaceutically acceptable salts and prodrugs thereof~~ or a pharmaceutically acceptable salt thereof,

wherein

------- represents an optional bond;

R^1 is H, $-(CH_2)_m-C(O)-(CH_2)_m-Z^1$, $-(CH_2)_m-Z^1$, $-(CH_2)_m-O-Z^1$ or $-(C_0-C_6)$alkyl-C(O)-NH-$(CH_2)_m-Z^3$;

Z^1 is an unsubstituted or substituted moiety selected from the group consisting of (C_1-C_{12})alkyl, benzo[b]thiophene, phenyl, naphthyl, benzo[b]furanyl, thiophene, isoxazolyl, indolyl,  ,  or  ;

R^2 is H or (C_1-C_6)alkyl;

or R^1 and R^2 are taken together with the nitrogen atoms to which they are attached to form a compound of formula (IIa), (IIb) or (IIc),


(IIa)


(IIb)

or


(IIc)

R^3 is $-(CH_2)_m-E-(CH_2)_m-Z^2$;

E is O, S, -C(O)-, -C(O)-O-, -NH-C(O)-O- or a bond;

Z^2 is H, (C_1-C_{12})alkyl, amino, (C_1-C_{12})alkylamino, N,N-di-(C_1-C_{12})alkylamino, (C_1-C_{12})alkylguanidino, or an ~~optionally substituted~~ unsubstituted or substituted moiety selected from the group

consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl and naphthyl;

R^4 is H or $-(CH_2)_m-A^1$;

A^1 is $-C(=Y)-N(X^1X^2)$, $-C(=Y)-X^2$, $-C(=NH)-X^2$ or X^2;

Y is O or S;

X^1 is H, (C_1-C_{12})alkyl, $-(CH_2)_m-NH-(C_1-C_6)$alkyl, $-(CH_2)_m-N-di-(C_1-C_6)$alkyl or $-(CH_2)_m-$aryl;

X^2 is $-(CH_2)_m-Y^1-X^3$ or an ~~optionally substituted~~ unsubstituted or substituted (C_1-C_{12})alkyl;

Y^1 is O, S, NH, C=O, (C_2-C_{12})alkenyl having one or more double bonds, -NH-CO-, -CO-NH-, $-NH-CO-O-(CH_2)_m-$, $-C\equiv C-$, SO_2 or a bond;

X^3 is H, an ~~optionally substituted~~ unsubstituted or substituted moiety selected from the group consisting of

(C_1-C_{12})alkyl, (C_3-C_8)cycloalkyl, (C_1-C_{12})alkoxy, aryloxy, (C_1-C_{12})alkylamino, N,N-di-(C_1-C_{12})alkylamino, -CH-di-(C_1-C_{12})alkoxy, pyrrolidinyl, pyridinyl, thiophene, imidazolyl, piperidinyl, piperazinyl, benzothiazolyl, furanyl, indolyl, morpholino, benzo[b]furanyl, quinolinyl, isoquinolinyl, $-(CH_2)_m-$phenyl, naphthyl, fluorenyl, phthalamidyl, pyrimidinyl,



or X^1 and X^2 are taken together with the nitrogen to which they are attached to form an ~~optionally substituted~~ unsubstituted or substituted moiety selected from the group consisting of

thiazolyl



Y^2 is CH-X^4, N-X^4, -C(X^4X^4), O or S;

X^4 for each occurrence is independently -$(CH_2)_m$-Y^3-X^5;

Y^3 is -C(O)-, -C(O)O- or a bond;

X^5 is hydroxy, (C_1-C_{12})alkyl, amino, (C_1-C_{12})alkylamino, N,N-di-(C_1-C_{12})alkylamino, or an ~~optionally substituted~~ unsubstituted or substituted moiety selected from the group consisting of aryl, aryl(C_1-C_4)alkyl, furanyl, pyridinyl, indolyl, piperidinyl, -CH(phenyl)$_2$,



;

R^5 is (C_1-C_{12})alkyl, (C_0-C_6)alkyl-C(O)-O-Z^5, (C_0-C_6)alkyl-C(O)-NH-$(CH_2)_m$-Z^3 or an ~~optionally substituted~~ unsubstituted or substituted aryl;

Z^3 for each occurrence is independently amino, (C_1-C_{12})alkylamino, amino(C_1-C_{12})alkyl, (C_5-C_7)cycloalkylamino, amino((C_5-C_7)cycloalkyl, N-(C_1-C_{12})alkylamino, N,N-di-(C_1-C_{12})alkylamino, (C_5-C_7)cycloalkyl,

↑
H_2N(C_1-C_6)alkyl-C(O)-O-(C_1-C_6)alkyl,

optionally-substituted phenyl-$(CH_2)_m$-O-C(O)-NH-$(C_1$-$C_6)$alkyl→
C(O)-O-$(C_1$-$C_6)$alkyl

or an ~~optionally substituted~~ unsubstituted or substituted moiety selected from the group consisting of imidazolyl,

pyridinyl, morpholino, piperidinyl, piperazinyl, pyrazolidinyl, furanyl, phenyl, indolyl and thiophene; provided that when m is 0 in the formula for R^5 then Z^3 is not -NH-C(O)-O$(CH_2)_m$-phenyl or -NH-C(O)-O-$(CH_2)_m$-$(C_1$-$C_6)$alkyl;

A1 R^6 is H or $(C_1$-$C_6)$alkyl;

R^7 is $(C_1$-$C_{12})$alkyl or -$(CH_2)_m$-Z^4;

Z^4 is an ~~optionally substituted~~ unsubstituted or substituted moiety selected from the group consisting of phenyl,

naphthyl, indolyl, thiophene, benzo[b]furan, benzo[b]thiophene, isoxazolyl,



;

Z^5 is H, $(C_1$-$C_{12})$alkyl, $(CH_2)_m$-aryl;

wherein an ~~optionally substituted~~ unsubstituted or substituted moiety is ~~optionally~~ substituted by one or more

substituents, each independently selected from the group consisting of Cl, F, Br, I, CF_3, CN, N_3, NO_2, OH, SO_2NH_2, -OCF_3, $(C_1$-$C_{12})$alkoxy, -$(CH_2)_m$-phenyl-$(X^6)_n$, -S-phenyl-$(X^6)_n$, -S-$(C_1$-$C_{12})$alkyl, -O-$(CH_2)_m$-phenyl-$(X^6)_n$, -$(CH_2)_m$-C(O)-O-$(C_1$-$C_6)$alkyl, -$(CH_2)_m$-C(O)-$(C_1$-$C_6)$alkyl, -O-$(CH_2)_m$-NH_2, -O-$(CH_2)_m$-NH-$(C_1$-$C_6)$alkyl, -O-$(CH_2)_m$-N-di-$((C_1$-$C_6)$alkyl), -$(C_0$-$C_{12})$alkyl-$(X^6)_n$ and -$(CH_2)_m$-phenyl-X^7;

X^6 for each occurrence is independently selected from the group consisting of hydrogen, Cl, F, Br, I, NO_2, N_3, CN, OH, -CF_3, -OCF_3, $(C_1$-$C_{12})$alkyl, $(C_1$-$C_{12})$alkoxy, -$(CH_2)_m$-NH_2, -$(CH_2)_m$-NH-$(C_1$-$C_6)$alkyl, -$(CH_2)_m$-N-di-$((C_1$-$C_6)$alkyl) and -$(CH_2)_m$-phenyl;

X^7 is -NH-C(=NH•HI)-X^8, wherein X^8 is thiophene, $(C_1$-$C_6)$alkyl or phenyl;

m for each occurrence is independently 0 or an integer from 1 to 6; and

n for each occurrence is independently an integer from 1 to 5;

provided that:

(a) when R^5 is $(C_1\text{-}C_{12})$alkyl or -C(O)-O-Z^5 and Z^5 is $(C_1\text{-}C_{12})$alkyl or an ~~optionally substituted~~ unsubstituted or substituted aryl; R^6 is H or $(C_1\text{-}C_6)$alkyl; R^7 is $(C_1\text{-}C_{12})$alkyl or Z^4 and Z^4 is thiophene or an ~~optionally substituted~~ unsubstituted or substituted phenyl, then R^3 is not -C(O)-O-$(CH_2)_m$-Z where m is 0 and Z is H or $(C_1\text{-}C_{12})$alkyl or where m is 1 to 6 and Z is H;

(b) when R^5 is $(C_1\text{-}C_{12})$alkyl or an ~~optionally substituted~~ unsubstituted or substituted phenyl; R^6 is H or $(C_1\text{-}C_{12})$alkyl; R^7 is $(C_1\text{-}C_{12})$alkyl and R^3 is -O-(CH_2)-Z^2, then Z^2 is not an ~~optionally substituted~~ unsubstituted or substituted moiety selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl, and naphthyl; ~~and~~

(c) when R^5 is H or $(C_1\text{-}C_{12})$alkyl; R^6 is $(C_1\text{-}C_6)$alkyl; R^7 is $(C_1\text{-}C_{12})$alkyl; and R^3 is -O-Z^2 or -S-Z^2, then Z^2 is not an ~~optionally substituted~~ unsubstituted or substituted moiety selected from the group consisting of phenyl, naphthyl, thiophene, benzothienyl and indolyl~~.~~; and

(d) when R^1 is H; R^2 is H; R^5 is a substituted aryl; and R^6 is H, R^3 is not -$(CH_2)_m$-E-$(CH_2)_m$-Z^2 wherein each occurrence of m is 0, E is a bond and Z^2 is H.

23. (Currently amended): A compound ~~according to claim 22~~ of the formula (R configuration)



wherein



Z^3 is $-CH_2-NH_2$, $-(CH_2)_2$, $-(CH_2)_3-NH_2$ or ;

R^3 is $-(CH_2)_m-E-(CH_2)_m-Z^2$;

E is O, S, -C(O)-, -C(O)-O-, -NH-C(O)-O- or a bond;

Z^2 is H, (C_1-C_{12})alkyl, amino, (C_1-C_{12})alkylamino, N,N-di-(C_1-C_{12})alkylamino, (C_1-C_{12})alkylguanidino, or an ~~optionally substituted~~ unsubstituted or substituted moiety selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl and naphthyl; and

X^1 is $-(CH_2)_2-N(CH_3)_2$ and X^2 is benzyl; or

A 1 X^1 and X^2 are taken together with the nitrogen atom to which they are attached, to form



,


,


,



or


or a pharmaceutically acceptable salt thereof.

24. (Currently amended): A compound according to claim ~~22~~ 23 of the formula (R configuration)



wherein

Z^3 is



or



;

and

X^1 is $-(CH_2)_2-N(CH_3)_2$ and X^2 is benzyl; or

X^1 and X^2 are taken together with the nitrogen atom to which they are attached, to form



,



,



,



or



.

25. (Withdrawn):

26. (Withdrawn):

27. (Currently amended): A compound according to claim ~~22~~ 23 of the formula



28. (Currently amended): A compound according to claim ~~22~~ 23 of the formula



29. (Withdrawn):

30. (Original): A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

31. (Withdrawn):

32. (Withdrawn):

33. (Original): A method of binding one or more of a somatostatin subtype receptor in a subject in need thereof, which comprises administering a compound according to claim 1 or a pharmaceutically acceptable salt thereof to said subject.

34. (Withdrawn):

35. (Withdrawn):

36. (Withdrawn):

37. (Withdrawn):

A1

38. (Withdrawn):

39. (Withdrawn):

40. (Withdrawn):

41. (Withdrawn):

42. (Withdrawn):

43. (Withdrawn):